Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Invasive Nos × Letrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 143 Endometrial Neoplasms 13 Ovarian Neoplasms 12 Fallopian Tube Neoplasms 5 Recurrence 4 Neoplasms 4 Neoplasm Metastasis 4 Carcinoma, Intraductal, Noninfiltrating 4 Breast Cancer Metastatic 3 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Lobular 2 Breast Diseases 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Polycystic Ovary Syndrome 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Pain 1 Osteoporosis 1 Neoplastic Cells, Circulating 1 Neoadjuvant Operable Breast Cancer 1 Multiple Endocrine Neoplasia Type 1 1 Medullary cystic kidney disease 1 1 Lymphangioleiomyomatosis 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡